Target to Lead Selection for ADCs and Biologics

Navigating the complexities of ADC development—such as poor therapeutic windows, tumor heterogeneity, and off-tumor effects—requires precise target and lead selection. Crown Bioscience, with the largest library of patient-derived systems, including PDX models and organoids, provides unmatched target validation. Advanced engineering capabilities, including the creation of isogenic pairs and resistant models, optimize ADCs for greater efficacy.

Through detailed tissue analysis using digital pathology and spatial biology, we identify key biomarkers that enhance therapeutic windows and reduce toxicity. By integrating these proven methods with innovative screening techniques, Crown Bioscience ensures a strong foundation for ADC project success, accelerating your path to clinical validation.

Why Choose Crown Bioscience for ADC Discovery and Development?

End-to-End Expertise: From antibody discovery to ADC manufacturing, we offer a fully integrated solution.
Advanced Technologies: Cutting-edge platforms for antibody screening, functional characterization, and bioanalysis.
Regulatory Support: IND-enabling safety assessments and compliance-driven bioanalytical services.
Scalability & Flexibility: Customizable workflows to support ADCs from early-stage research to clinical trials.

Contact Us

Phage Display Antibody Discovery: Accelerated Antibody Identification

Harness the power of our advanced phage display platforms to rapidly discover high-affinity antibody hits. Identify a diverse and developable panel of candidates against your target of interest while screening for epitope specificity and cross-species reactivity. Our optimized workflows support the early stages of ADC (antibody-drug conjugate) development, ensuring a strong foundation for success.

Comprehensive Antibody Characterization for Informed Candidate Selection

Selecting the right antibody is critical for therapeutic success. Our in vitro antibody characterization services provide thorough profiling, including target binding, off-target assessments, and developability studies. These early insights streamline ADC generation and help de-risk your drug development pipeline.

Efficient ADC Generation with Flexible Linker and Payload Options

Our integrated ADC development services include customized linker-payload selection, iterative conjugation strategies, and in-depth stability profiling. We offer a wide range of conjugation methods and analytical tools to optimize the drug-to-antibody ratio (DAR), ensuring a well-characterized and potent ADC candidate.

Advanced In Vitro Functional Characterization for ADC Validation

Evaluate your ADC's mechanism of action (MoA) with our suite of functional assays. Our capabilities include target binding, ADC internalization studies, and tumor cell killing potency assessments. We leverage cutting-edge 3D spheroid and tumoroid platforms to enhance translational relevance and improve predictive accuracy.

Off-Target Binding Analysis for Enhanced ADC Safety

Minimizing off-target effects is crucial for ADC safety and efficacy. Our proprietary cell-based microarray technology enables high-throughput binding specificity assessments, providing a comprehensive understanding of antibody and payload interactions. Gain confidence in your ADC’s selectivity with our robust off-target screening solutions.

Translational In Vivo Pharmacology & Preclinical Models

Support your ADC efficacy studies with our diverse portfolio of translational models. We offer patient-derived xenografts (PDX), syngeneic, and humanized models to simulate real-world tumor biology. Our extensive cancer model database allows researchers to identify the most relevant tumor models for their studies. Additionally, we provide pharmacokinetics (PK) assessments to quantify intact ADCs, antibodies, and small-molecule payloads.

FACTSHEET

Integrated Translational Services for Antibody-Drug Conjugates Development

Download Now

WHITE PAPER

Harnessing Integrated Preclinical Solutions to Accelerate Bispecific Antibody Development

Download Now

Integrated Safety Services & IND-Enabling Studies

Ensure regulatory success with our comprehensive in vitro and in vivo safety profiling. Our services include immunogenicity assessments, tissue cross-reactivity studies, and IND-enabling toxicology evaluations in human primary tissues, organoid cultures, and 3D tumoroids. We also support non-GLP and GLP pharmacology-toxicology studies for early tolerability and safety assessments.

End-to-End ADC Bioanalytical Testing & Stability Studies

From method development and validation to cGMP-compliant clinical product release, our ADC bioanalytical testing services support the entire drug development life cycle. Our extensive experience ensures compliance with regulatory requirements while delivering high-quality data for decision-making.

What is phage display antibody discovery?

Phage display is a technology used to rapidly identify high-affinity antibodies by screening a diverse library of candidates. It helps in selecting developable antibodies for targeted therapies, including ADCs.

How do you characterize antibodies for ADC development?

We conduct in vitro profiling, including target binding and off-target assessments, and evaluate developability factors such as stability and aggregation to ensure the best candidates for ADC generation.

What linker and payload options do you offer for ADCs?

We offer a broad selection of customizable linkers and payloads, along with optimized conjugation strategies to enhance ADC efficacy, stability, and drug-to-antibody ratio (DAR).

What functional assays are available for ADC validation?

We provide target binding and internalization studies, tumor cell killing potency assays, and bystander killing assays, and advanced 3D spheroid and tumoroid models to evaluate ADC mechanism of action.

How do you ensure ADC safety and minimize off-target effects?

We use high-throughput binding specificity assessments and proprietary cell-based microarray technology to comprehensively evaluate off-target interactions and enhance ADC selectivity.

What in vivo models are available for ADC efficacy studies?

Our in vivo models include patient-derived xenografts (PDX), syngeneic, and humanized models, along with pharmacokinetics (PK) assessments to quantify ADC exposure and performance.

What safety studies do you offer for ADC development?

We provide immunogenicity assessments, tissue cross-reactivity studies, and IND-enabling toxicology evaluations in human tissues, organoids, and tumoroid cultures.

What bioanalytical testing services do you provide?

Our services include method development, validation, and cGMP-compliant clinical product release, ensuring comprehensive bioanalytical support throughout ADC development.

Can you scale up ADC manufacturing for clinical trials?

Yes, through our sister company KBI Biopharma, we provide seamless scale-up and GMP-compliant manufacturing services, covering payload synthesis, linker-payload conjugation, and ADC production for early-phase clinical trials.

How can I start working with you for ADC development?

Contact us to discuss your project requirements. Our experts will guide you through discovery, development, and manufacturing, offering tailored solutions to accelerate your ADC program.